101 related articles for article (PubMed ID: 9346852)
1. Recombinant epithelial cell mucin (MUC-1) expressed in baculovirus resembles antigenically tumor associated mucin, target for cancer immunotherapy.
Ciborowski P; Finn OJ
Biomed Pept Proteins Nucleic Acids; 1995; 1(3):193-8. PubMed ID: 9346852
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer associated mucin: a review.
Segal-Eiras A; Croce MV
Allergol Immunopathol (Madr); 1997; 25(4):176-81. PubMed ID: 9269507
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human tumor antigen MUC1 expressed in insect cells: structure and immunogenicity.
Soares M; Hanisch FG; Finn OJ; Ciborowski P
Protein Expr Purif; 2001 Jun; 22(1):92-100. PubMed ID: 11388805
[TBL] [Abstract][Full Text] [Related]
4. Immunity to murine breast cancer cells modified to express MUC-1, a human breast cancer antigen, in transgenic mice tolerant to human MUC-1.
Carr-Brendel V; Markovic D; Ferrer K; Smith M; Taylor-Papadimitriou J; Cohen EP
Cancer Res; 2000 May; 60(9):2435-43. PubMed ID: 10811121
[TBL] [Abstract][Full Text] [Related]
5. Flow cytometry-based assay to evaluate human serum MUC1-Tn antibodies.
Van Elssen CH; Clausen H; Germeraad WT; Bennet EP; Menheere PP; Bos GM; Vanderlocht J
J Immunol Methods; 2011 Feb; 365(1-2):87-94. PubMed ID: 21194532
[TBL] [Abstract][Full Text] [Related]
6. Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.
Tsang KY; Palena C; Yokokawa J; Arlen PM; Gulley JL; Mazzara GP; Gritz L; Yafal AG; Ogueta S; Greenhalgh P; Manson K; Panicali D; Schlom J
Clin Cancer Res; 2005 Feb; 11(4):1597-607. PubMed ID: 15746065
[TBL] [Abstract][Full Text] [Related]
7. Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody.
Akewanlop C; Watanabe M; Singh B; Walker M; Kufe DW; Hayes DF
Cancer Res; 2001 May; 61(10):4061-5. PubMed ID: 11358826
[TBL] [Abstract][Full Text] [Related]
8. Selection and characterization of anti-MUC-1 scFvs intended for targeted therapy.
Winthrop MD; DeNardo SJ; Albrecht H; Mirick GR; Kroger LA; Lamborn KR; Venclovas C; Colvin ME; Burke PA; DeNardo GL
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3845S-53S. PubMed ID: 14506182
[TBL] [Abstract][Full Text] [Related]
9. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.
Sørensen AL; Reis CA; Tarp MA; Mandel U; Ramachandran K; Sankaranarayanan V; Schwientek T; Graham R; Taylor-Papadimitriou J; Hollingsworth MA; Burchell J; Clausen H
Glycobiology; 2006 Feb; 16(2):96-107. PubMed ID: 16207894
[TBL] [Abstract][Full Text] [Related]
10. Biochemical characterization of the soluble form of tumor antigen MUC1 isolated from sera and ascites fluid of breast and pancreatic cancer patients.
Beatty P; Hanisch FG; Stolz DB; Finn OJ; Ciborowski P
Clin Cancer Res; 2001 Mar; 7(3 Suppl):781s-787s. PubMed ID: 11300473
[TBL] [Abstract][Full Text] [Related]
11. Design and expression of a synthetic mucin gene fragment in Escherichia coli.
Dolby N; Dombrowski KE; Wright SE
Protein Expr Purif; 1999 Feb; 15(1):146-54. PubMed ID: 10024481
[TBL] [Abstract][Full Text] [Related]
12. Nuclear magnetic resonance-based dissection of a glycosyltransferase specificity for the mucin MUC1 tandem repeat.
Brokx RD; Revers L; Zhang Q; Yang S; Mal TK; Ikura M; Gariépy J
Biochemistry; 2003 Dec; 42(47):13817-25. PubMed ID: 14636048
[TBL] [Abstract][Full Text] [Related]
13. Expression of mucin (MUC-1) from a mini-Epstein-Barr virus in immortalized B-cells to generate tumor antigen specific cytotoxic T cells.
Kilger E; Pecher G; Schwenk A; Hammerschmidt W
J Gene Med; 1999; 1(2):84-92. PubMed ID: 10738572
[TBL] [Abstract][Full Text] [Related]
14. [Vaccination against the tumoral mammary epithelial cells expressing MUC1 mucin].
Scholl SM; Pouillart P
Bull Cancer; 1997 Jan; 84(1):61-4. PubMed ID: 9180861
[TBL] [Abstract][Full Text] [Related]
15. Structurally defined synthetic cancer vaccines: analysis of structure, glycosylation and recognition of cancer associated mucin, MUC-1 derived peptides.
Liu X; Sejbal J; Kotovych G; Koganty RR; Reddish MA; Jackson L; Gandhi SS; Mendonca AJ; Longenecker BM
Glycoconj J; 1995 Oct; 12(5):607-17. PubMed ID: 8595249
[TBL] [Abstract][Full Text] [Related]
16. Modulation of MUC1 mucin as an escape mechanism of breast cancer cells from autologous cytotoxic T-lymphocytes.
Kontani K; Taguchi O; Narita T; Izawa M; Hiraiwa N; Zenita K; Takeuchi T; Murai H; Miura S; Kannagi R
Br J Cancer; 2001 May; 84(9):1258-64. PubMed ID: 11336479
[TBL] [Abstract][Full Text] [Related]
17. Technology evaluation: BLP-25, Biomira Inc.
Morse MA
Curr Opin Mol Ther; 2001 Feb; 3(1):102-5. PubMed ID: 11249725
[TBL] [Abstract][Full Text] [Related]
18. Recombinant MUC1 mucin with a breast cancer-like O-glycosylation produced in large amounts in Chinese-hamster ovary cells.
Bäckström M; Link T; Olson FJ; Karlsson H; Graham R; Picco G; Burchell J; Taylor-Papadimitriou J; Noll T; Hansson GC
Biochem J; 2003 Dec; 376(Pt 3):677-86. PubMed ID: 12950230
[TBL] [Abstract][Full Text] [Related]
19. Development and preclinical evaluation of a Bacillus Calmette-Guérin-MUC1-based novel breast cancer vaccine.
Chung MA; Luo Y; O'Donnell M; Rodriguez C; Heber W; Sharma S; Chang HR
Cancer Res; 2003 Mar; 63(6):1280-7. PubMed ID: 12649188
[TBL] [Abstract][Full Text] [Related]
20. N-Glycosylation of the MUC1 mucin in epithelial cells and secretions.
Parry S; Hanisch FG; Leir SH; Sutton-Smith M; Morris HR; Dell A; Harris A
Glycobiology; 2006 Jul; 16(7):623-34. PubMed ID: 16585136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
